(Q51554552)

7 April 2018

title

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. (English)

1 reference

7 April 2018

0 references

1 reference

1 reference

1 reference

Ponssen HH

1

1 reference

7 April 2018

Elte JW

2

1 reference

7 April 2018

Lehert P

3

1 reference

7 April 2018

Schouten JP

4

1 reference

7 April 2018

Bets D

5

1 reference

7 April 2018

publication date

1 June 2000

1 reference

7 April 2018

published in

Clinical Therapeutics

1 reference

7 April 2018

volume

22

1 reference

7 April 2018

issue

6

1 reference

7 April 2018

page(s)

709-718

1 reference

7 April 2018

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Insulin and atheroma. 20-yr perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Beta-cell deficiency, insulin resistance, or both?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

1 reference

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

The insulin-sparing effect of metformin in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

The two-period cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Management of Non-Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

1 reference

7 January 2021

Metformin and metoprolol CR treatment in non-obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Cholesterol Lowering Effect of Metformin in Combined Hyperlipidemia: Placebo Controlled Double Blind Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Insulin and Cardiovascular Disease: Paris Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Current approaches to measurement of insulin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

1 reference

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2990005-5

7 January 2021

10.1016/S0149-2918(00)90005-5

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10929918

1 reference

7 April 2018